Altimmune, Inc. (ALT) News
Filter ALT News Items
ALT News Results
|Loading, please wait...|
ALT News Highlights
- ALT's 30 day story count now stands at 3.
- Over the past 7 days, the trend for ALT's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about ALT are EM, GLP and LI.
Latest ALT News From Around the Web
Below are the latest news stories about ALTIMMUNE INC that investors may wish to consider to help them evaluate ALT as an investment opportunity.
Altimmune Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update
Interim 24-week readout from MOMENTUM Phase 2 obesity trial expected March 2023 Initiation of Phase 2b non-alcoholic steatohepatitis (NASH) trial expected mid-2023 Webcast to be held today, February 28, 2023, at 8:30 am ET GAITHERSBURG, Md., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update. “The next twelve-mont
Altimmune: Potential Dual Action For Pemvidutide In Obesity, NASH
Investment Thesis Summary
A rich vein of risk-reward has bestowed the financial markets in early FY23, despite bountiful macro-pressures that still linger from the FY22 selloff. Chiefly, central bank tightening [a‘ la "The Fed"], looming recession probabilities, and, to be brutally honest, a broad disconnect in risk-appetite to these underlying economic realities. There's argument the rally has been spurred on by short covering and is more a squeeze than an organic rally. Nevertheless, there are still numerous long-term opportunities for those patient enough to sift through the market generated data. With security selection, we're rigorously analyzing companies presenting with exciting growth prospects, robust profitability characteristics and the potential for valuati...
Altimmune to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023
GAITHERSBURG, Md., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2022 financial results on Tuesday, February 28, 2023 and will provide a business update. Altimmune management will host a conference call at 8:30 am E.T. on February 28 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations
7 Small-Cap Stocks with Big Growth Potential in 2023
Some of the greatest opportunities can be found in these small-cap stocks to buy.
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 7, 2023
GAITHERSBURG, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Stephen A. Harrison, Chairman and Co-Founder, Pinnacle Clinical Research and Summit Clinical Research, will deliver an oral presentation of the results of Altimmune’s recently completed 12-week Phase 1b and 12-week extension trials of pemvidutide in subjects with non-alcoholic fatty liver disease (NAFLD) at the NASH-TAG Conference, which will be
Altimmune Appoints Raymond Jordt as Chief Business Officer
Mr. Jordt brings over 25 years of industry experience in corporate strategy and business developmentGAITHERSBURG, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Raymond Jordt as Chief Business Officer, effective January 1, 2023. Mr. Jordt succeeds José Ochoa, who is leaving Altimmune to pursue other opportunities. Mr. Jordt is an accomplished executive with over 25 years of experience in the pha
Altimmune Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD)
Greater than 75% relative reduction in liver fat content achieved at the 1.8 mg and 2.4 mg doses at 24 weeksSignificant reductions in serum alanine aminotransferase (ALT) and corrected T1 (cT1) observed, both established markers of liver inflammationMean weight loss of 7.2% (placebo adjusted 6.0%) in subjects without diabetes at the 1.8 mg doseGlycemic control maintained with trends toward improvements in fasting glucose and HbA1c in subjects with diabetesMeaningful reductions in blood pressure
The 7 Hottest Biotech Stocks to Own in 2023 and Beyond
Some of the hottest biotech stocks are safe and recession-proof.
Altimmune to Participate at Two Upcoming Investor Conferences
GAITHERSBURG, Md., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate at the following investor conferences: Evercore ISI 5th Annual HealthCONx Virtual ConferenceTuesday, November 29, 2022Fireside chat at 10:55 am Eastern Time Piper Sandler 34th Annual Healthcare Conference in New York, NYThursday, December 1, 2022Fireside chat at 10:00 am Eastern Time The sess
Analysts Offer Insights on Healthcare Companies: Altimmune (ALT), 89bio (ETNB) and Avadel Pharmaceuticals (AVDL)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Altimmune (ALT – Research Report), 89bio (ETNB – Research Report) and Avadel Pharmaceuticals (AVDL – Research Report) with bullish sentiments. Altimmune (ALT) In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Altimmune, with a price target of $50.00. The company's shares closed last Friday at $8.84. According to TipRanks.